Related Experiment Video

Updated: Mar 22, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Afatinib Is Active in Platinum-Refractory ERBB-Mutant Urothelial Carcinoma

    Cancer Discovery
    |April 16, 2016
    PubMed

    Insights

    HER2 or ERBB3 alterations predict afatinib response in urothelial cancer. This finding offers new hope for patients with refractory disease.

    Area of Science:

    • Oncology
    • Genetics
    • Pharmacology

    Background:

    • Urothelial carcinoma is a significant cause of cancer-related mortality.
    • Treatment options for refractory urothelial carcinoma are limited.
    • Targeted therapies are emerging as a promising treatment modality.

    Discussion:

    • HER2 (Human Epidermal growth factor Receptor 2) and ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3) alterations were investigated as predictive biomarkers.
    • Afatinib, a tyrosine kinase inhibitor, was evaluated for its efficacy in patients with these specific genetic alterations.
    • The study focused on patients with refractory urothelial carcinomas, a population with unmet clinical needs.

    Key Insights:

    • Specific alterations in HER2 or ERBB3 are associated with a positive response to afatinib treatment.
    • These genetic markers can identify patients likely to benefit from afatinib therapy.
    • This suggests a personalized medicine approach for refractory urothelial cancer.

    Outlook:

    • Further clinical trials are warranted to validate these findings in a larger patient cohort.
    • Afatinib could become a targeted treatment option for a subset of urothelial carcinoma patients.
    • Biomarker-driven therapy holds potential to improve outcomes in refractory cancers.

    More Related Videos

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

    Published on: October 23, 2019

    8.4K
    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    1.1K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.4K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    65